» Articles » PMID: 16243916

Mesenchymal Stem Cell Adhesion to Cardiac Microvascular Endothelium: Activators and Mechanisms

Overview
Date 2005 Oct 26
PMID 16243916
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating stem cells home within the myocardium, probably as the first step of a tissue regeneration process. This step requires adhesion to cardiac microvascular endothelium (CMVE). In this study, we studied mechanisms of adhesion between CMVE and mesenchymal stem cells (MSCs). Adhesion was studied in vitro and in vivo. Isolated 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-labeled rat MSCs were allowed to adhere to cultured CMVE in static and dynamic conditions. Either CMVE or MSCs were pretreated with cytokines [IL-1beta, IL-3, IL-6, stem cell factor, stromal cell-derived factor-1, or TNF-alpha, 10 ng/ml]. Control or TNF-alpha-treated MSCs were injected intracavitarily in rat hearts in vivo. In baseline in vitro conditions, the number of MSCs that adhered to CMVE was highly dependent on the flow rate of the superfusing medium but remained significant at venous and capillary shear stress amplitudes. Activation of both CMVE and MSCs with TNF-alpha or IL-1beta before adhesion concentration dependently increased adhesion of MSCs at each studied level of shear stress. Consistently, in vivo, activation of MSCs with TNF-alpha before injection significantly enhanced cardiac homing of MSCs. TNF-alpha-induced adhesion could be completely blocked by pretreating either CMVE or MSCs with anti-VCAM-1 monoclonal antibodies but not by anti-ICAM-1 antibodies. Adhesion of circulating MSCs in the heart appears to be an endothelium-dependent process and is sensitive to modulation by activators of both MSCs and endothelium. Inflammation and the expression of VCAM-1 but not ICAM-1 on both cell types have a regulatory effect on MSC homing in the heart.

Citing Articles

Mesenchymal stromal cells as cancer promoters.

Antoon R, Overdevest N, Saleh A, Keating A Oncogene. 2024; 43(49):3545-3555.

PMID: 39414984 PMC: 11602730. DOI: 10.1038/s41388-024-03183-1.


Rebuilding the myocardial microenvironment to enhance mesenchymal stem cells-mediated regeneration in ischemic heart disease.

Chu Q, Jiang X, Xiao Y Front Bioeng Biotechnol. 2024; 12:1468833.

PMID: 39372432 PMC: 11452912. DOI: 10.3389/fbioe.2024.1468833.


Mesenchymal Stem Cell Membrane-Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia-Reperfusion Injury Prevention.

Chen H, Yin W, Yao K, Liang J, Cai J, Sui X Adv Sci (Weinh). 2024; 11(32):e2404171.

PMID: 39031840 PMC: 11348201. DOI: 10.1002/advs.202404171.


The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS-A Review Focusing on Neuroprotective Properties.

Gavasso S, Krakenes T, Olsen H, Evjenth E, Ytterdal M, Haugsoen J Int J Mol Sci. 2024; 25(3).

PMID: 38338644 PMC: 10855165. DOI: 10.3390/ijms25031365.


Influence of SPIO labelling on the function of BMSCs in chemokine receptors expression and chemotaxis.

Liu Y, Huang W, Wang H, Lu W, Guo J, Yu L PeerJ. 2023; 11:e15388.

PMID: 37283891 PMC: 10241165. DOI: 10.7717/peerj.15388.